Literature DB >> 14960617

Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation.

Stacy A Castner1, Patricia S Goldman-Rakic.   

Abstract

A natural consequence of aging is a loss of dopamine function and associated deficits in working memory in both human and nonhuman primates. Specifically, deficiency of D1 receptor signaling has been implicated in age-related cognitive decline. Here, we report that an intermittent, sensitizing regimen of the D1 dopamine agonist ABT-431 dramatically enhances working memory performance in aged rhesus monkeys, while either producing impairment or having little effect on performance in young adult monkeys. Importantly, cognitive enhancement in the aged monkeys was still evident for >1 year after cessation of D1 treatment. Because intermittent exposure to low doses of amphetamine and other stimulants has been shown to enhance responsiveness to subsequent stimulant exposure, our findings suggest that sensitization of D1 signaling may provide a novel neurobiological mechanism for improving a core cognitive process in conditions in which dopamine function has deteriorated, such as in normal aging and Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14960617      PMCID: PMC6730346          DOI: 10.1523/JNEUROSCI.3987-03.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

1.  Aging and stress: past hypotheses, present approaches and perspectives.

Authors:  Pedro Garrido
Journal:  Aging Dis       Date:  2011-01-28       Impact factor: 6.745

Review 2.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

3.  Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation.

Authors:  Sasha E B Gibbs; Mark D'Esposito
Journal:  Cogn Affect Behav Neurosci       Date:  2005-06       Impact factor: 3.282

4.  Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites.

Authors:  Kathryn D Luderman; Jennie L Conroy; R Benjamin Free; Noel Southall; Marc Ferrer; Marta Sanchez-Soto; Amy E Moritz; Blair K A Willette; Tim J Fyfe; Prashi Jain; Steve Titus; Lisa A Hazelwood; Jeffrey Aubé; J Robert Lane; Kevin J Frankowski; David R Sibley
Journal:  Mol Pharmacol       Date:  2018-08-01       Impact factor: 4.436

5.  AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs.

Authors:  J A O'Connor; E C Muly; S E Arnold; S E Hemby
Journal:  Schizophr Res       Date:  2006-12-01       Impact factor: 4.939

6.  The effects of psychotomimetic and putative cognitive-enhancing drugs on the performance of a n-back working memory task in rats.

Authors:  Tracey Ko; John Evenden
Journal:  Psychopharmacology (Berl)       Date:  2008-09-30       Impact factor: 4.530

7.  Neural Protein Synthesis during Aging: Effects on Plasticity and Memory.

Authors:  Lesley A Schimanski; Carol A Barnes
Journal:  Front Aging Neurosci       Date:  2010-08-06       Impact factor: 5.750

Review 8.  Mechanisms of memory enhancement.

Authors:  Sarah A Stern; Cristina M Alberini
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2012-11-13

Review 9.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

10.  Expression profiles of schizophrenia susceptibility genes during human prefrontal cortical development.

Authors:  Kwang H Choi; Megan E Zepp; Brandon W Higgs; Cynthia S Weickert; Maree J Webster
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.